We retrospectively investigated the clinical characteristics of human herpesvirus 6 (HHV-6) meningoencephalitis within 100 days after allogeneic hematopoietic stem cell transplantation (HSCT). Of 1148 patients who received transplants between January 1999 and December 2003, 11 patients (0.96%) with HHV-6 meningoencephalitis were identified. Ten of 11 recipients received hematopoietic stem cells from donors other than HLA-identical siblings. Confusion was the most frequent central nervous system (CNS) symptom, and a skin rash with high-grade fever preceded the CNS symptoms in 9 patients. Magnetic resonance imaging of the brain showed an abnormal increased T2 signal in the hypothalamus of 5 patients. Eight patients were treated with ganciclovir, and an improvement of CNS symptoms was obtained in 3 patients; 3 patients treated with acyclovir showed no improvement. Improvement in the meningoencephalitis seemed less frequent in patients with abnormal findings in the hypothalamus than in those without such findings. Because the symptoms of HHV-6 meningoencephalitis mimicked those of cyclosporine- or tacrolimus-induced encephalopathy, the drugs were withdrawn at the onset of CNS symptoms in 10 patients, resulting in the development of grade IV graft-versus-host disease (GVHD) in 5 patients.Three patients died of HHV-6 menin-goencephalitis, and 6 died of other causes, including GVHD. In conclusion, HHV-6 meningoencephalitis is a rare but potentially life-threatening complication in patients who undergo allogeneic HSCT. Careful assessment of the clinical findings and the brain may allow early and precise diagnosis of HHV-6 meningoencephalitis and contribute to improving its prognosis.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33:829–833.
Yoshida H, Matsunaga K, Ueda T, et al. Human herpesvirus 6 meningoencephalitis successfully treated with ganciclovir in a patient who underwent allogeneic bone marrow transplantation from an HLA-identical sibling. Int J Hematol. 2002;75:421–425.
Drobyski WR, Knox KK, Majewski D, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med. 1994;330:1356–1360.
Cole PD, Stiles J, Boulad F, et al. Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis. 1998;27:653–654.
Bosi A, Zazzi M, Amantini A, et al. Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bone Marrow Transplant. 1998;22:285–288.
Rieux C, Gautheret-Dejean A, Challine-Lehmann D, Kirch C, Agut H, Vernant JP. Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplantation. Transplantation. 1998;65:1408–1411.
Tsujimura H, Iseki T, Date Y, et al. Human herpesvirus-6 encephalitis after bone marrow transplantation: magnetic resonance imaging could identify the involved sites of encephalitis. Eur J Haematol. 1998;61:284–285.
Bethge W, Beck R, Jahn G, Mundinger P, Kanz L, Einsele H. Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation. Bone Marrow Transplant. 1999;24:1245–1248.
De Almeida Rodrigues G, Nagendra S, Lee C-K, De Magalhaes-Silverman M. Human herpes virus 6 fatal encephalitis in a bone marrow recipient. Scand J Infect Dis. 1999;31:313–315.
Kawano Y, Miyazaki T, Watanabe T, et al. HLA-mismatched CD34-selected stem cell transplant complicated by HHV-6 reactivation in the central nervous system. Bone Marrow Transplant. 2000;25:787–790.
Muta T, Kamo M, Gondo H, et al. Human herpesvirus-6 encephalitis followed by severe acute GVHD after a stem cell transplant from a microchimeric non-inherited maternal antigen (NIMA)-mismatched sibling. Bone Marrow Transplant. 2005;35:411–413.
Zerr DM, Gupta D, Huang M-L, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:309–317.
Wang F-Z, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis. 1999;28:562–568.
Tanaka N, Kimura H, Hoshino Y, et al. Monitoring four her-pesviruses in unrelated cord blood transplantation. Bone Marrow Transplant. 2000;26:1193–1197.
Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol. 1991;72:1401–1408.
Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998;66:1330–1334.
Sashihara J, Tanaka-Taya K, Tanaka S,et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002;100:2005–2011.
Ljungman P, Wang FZ, Clark DA, et al. High levels of human her-pesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol. 2000;111:774–781.
Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis. 2002;185:847–853.
Appleton AL, Sviland L, Peiris JSM, et al. Human herpes virus-6 infection in marrow graft recipients: role in pathogenesis of graft-versus-host disease. Newcastle upon Tyne Bone Marrow Transport Group. Bone Marrow Transplant. 1995;16:777–782.
Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol. 2001;50:612–619.
MacLean HJ, Douen AG. Severe amnesia associated with human herpesvirus 6 encephalitis after bone marrow transplantation. Transplantation. 2002;73:1086–1089.
Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122:128–134.
Singh N, Carrigan DR. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med. 1996;124:1065–1071.
Wang F-Z, Dahl H, Linde A, Brytting M, Ehrnst A, Ljungman P. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood. 1996;88:3615–3620.
De Bolle L, Manichanh C, Agut H, De Clercq E, Naesens L. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res. 2004;64:17–25.
Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:595–598.
About this article
Cite this article
Fujimaki, K., Mori, T., Kida, A. et al. Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Int J Hematol 84, 432–437 (2006). https://doi.org/10.1532/IJH97.06072
- Human herpesvirus 6
- Allogeneic hematopoietic stem cell transplantation
- Graft-versus-host disease
- Neurologic symptoms